

# Anthony J Garcia-Prats

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6836001/anthony-j-garcia-prats-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62  
papers

842  
citations

15  
h-index

26  
g-index

71  
ext. papers

1,077  
ext. citations

7.3  
avg, IF

3.98  
L-index

#	Paper	IF	Citations
62	Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. <i>PLoS Medicine</i> , <b>2018</b> , 15, e1002591	11.6	61
61	Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 60, 549-56	11.6	54
60	Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. <i>European Respiratory Journal</i> , <b>2016</b> , 48, 938-43	13.6	53
59	Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet Respiratory Medicine</i> , <b>2018</b> , 6, 265-275	35.1	50
58	New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 195, 1300-1310	10.2	46
57	Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations. <i>Tuberculosis</i> , <b>2014</b> , 94, 93-104	2.6	44
56	Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 2948-51	5.9	41
55	Fluoroquinolones for the treatment of tuberculosis in children. <i>Tuberculosis</i> , <b>2015</b> , 95, 229-45	2.6	38
54	A review of the use of ethionamide and prothionamide in childhood tuberculosis. <i>Tuberculosis</i> , <b>2016</b> , 97, 126-36	2.6	34
53	Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	28
52	Adverse effects of oral second-line antituberculosis drugs in children. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 1369-81	4.1	21
51	Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies. <i>PLoS Medicine</i> , <b>2019</b> , 16, e1002789	11.6	18
50	Managing multidrug-resistant tuberculosis in children: review of recent developments. <i>Current Opinion in Infectious Diseases</i> , <b>2014</b> , 27, 211-9	5.4	18
49	Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children. <i>Expert Review of Clinical Pharmacology</i> , <b>2018</b> , 11, 233-244	3.8	16
48	Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis. <i>Lancet Respiratory Medicine</i> , <b>2018</b> , 6, 662-664	35.1	16
47	Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 6073-9	5.9	15
46	Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 2384	3.8	15

45	Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons. <i>PLoS Medicine</i> , <b>2019</b> , 16, e1002882	11.6	14
44	Clinical and Cardiac Safety of Long-term Levofloxacin in Children Treated for Multidrug-resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 1777-1780	11.6	14
43	Completeness and accuracy of electronic recording of paediatric drug-resistant tuberculosis in Cape Town, South Africa. <i>Public Health Action</i> , <b>2013</b> , 3, 214-9	0.9	13
42	False-negative post-18-month confirmatory HIV tests in HIV DNA PCR-positive children: a retrospective analysis. <i>Aids</i> , <b>2012</b> , 26, 1927-34	3.5	13
41	Probable Levofloxacin-associated Secondary Intracranial Hypertension in a Child With Multidrug-resistant Tuberculosis. <i>Pediatric Infectious Disease Journal</i> , <b>2016</b> , 35, 706-8	3.4	13
40	Acquired drug resistance during inadequate therapy in a young child with tuberculosis. <i>Pediatric Infectious Disease Journal</i> , <b>2014</b> , 33, 883-5	3.4	12
39	Antituberculosis drugs in children. <i>Clinical Pharmacology and Therapeutics</i> , <b>2015</b> , 98, 252-65	6.1	12
38	Tuberculosis: opportunities and challenges for the 90-90-90 targets in HIV-infected children. <i>Journal of the International AIDS Society</i> , <b>2015</b> , 18, 20236	5.4	12
37	The safety and tolerability of the second-line injectable antituberculosis drugs in children. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 1491-1500	4.1	11
36	Listening panel agreement and characteristics of lung sounds digitally recorded from children aged 1-59 months enrolled in the Pneumonia Etiology Research for Child Health (PERCH) case-control study. <i>BMJ Open Respiratory Research</i> , <b>2017</b> , 4, e000193	5.6	11
35	Children exposed to multidrug-resistant tuberculosis at a home-based day care centre: a contact investigation. <i>International Journal of Tuberculosis and Lung Disease</i> , <b>2014</b> , 18, 1292-8	2.1	11
34	Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP). <i>Trials</i> , <b>2018</b> , 19, 693	2.8	11
33	Treatment Outcomes in Global Systematic Review and Patient Meta-Analysis of Children with Extensively Drug-Resistant Tuberculosis. <i>Emerging Infectious Diseases</i> , <b>2019</b> , 25, 441-450	10.2	10
32	Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	10
31	Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 589-598	4	9
30	Treatment of Multidrug-Resistant Tuberculosis Infection in Children. <i>Pediatric Infectious Disease Journal</i> , <b>2018</b> , 37, 1061-1064	3.4	9
29	Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa. <i>EClinicalMedicine</i> , <b>2020</b> , 20, 100290	11.3	8
28	Treatment of Multidrug-resistant Tuberculosis Infection in Children. <i>Pediatric Infectious Disease Journal</i> , <b>2018</b> , 37, 831-834	3.4	7

27	Feasibility of Identifying Household Contacts of Rifampin-and Multidrug-resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 425-435	11.6	7
26	Tuberculous Pericardial Effusions in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , <b>2018</b> , 7, 346-349	4.8	6
25	Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study. <i>The Lancet Child and Adolescent Health</i> , <b>2019</b> , 3, 636-645	14.5	6
24	Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	5
23	Successful Treatment of a Child With Extensively Drug-Resistant Tuberculous Meningitis. <i>Journal of the Pediatric Infectious Diseases Society</i> , <b>2015</b> , 4, e41-4	4.8	5
22	Effect of Coadministration of Lidocaine on the Pain and Pharmacokinetics of Intramuscular Amikacin in Children With Multidrug-Resistant Tuberculosis: A Randomized Crossover Trial. <i>Pediatric Infectious Disease Journal</i> , <b>2018</b> , 37, 1199-1203	3.4	5
21	HIV-associated pediatric tuberculosis: prevention, diagnosis and treatment. <i>Current Opinion in HIV and AIDS</i> , <b>2018</b> , 13, 501-506	4.2	5
20	Drug-resistant tuberculosis: will grand promises fail children and adolescents?. <i>The Lancet Child and Adolescent Health</i> , <b>2018</b> , 2, 237-238	14.5	4
19	Multidrug-Resistant Tuberculosis in Children: Recent Developments in Diagnosis, Treatment and Prevention. <i>Current Pediatrics Reports</i> , <b>2016</b> , 4, 53-62	0.7	4
18	Toxicity and tolerability of fluoroquinolone-based preventive therapy for childhood contacts of multidrug-resistant tuberculosis. <i>Pediatric Infectious Disease Journal</i> , <b>2014</b> , 33, 1098-9	3.4	4
17	Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	4
16	Acceptability of a Novel Levofloxacin Dispersible Tablet Formulation in Young Children Exposed to Multidrug-resistant Tuberculosis. <i>Pediatric Infectious Disease Journal</i> , <b>2019</b> , 38, 608-610	3.4	3
15	Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 3237-3246	5.1	3
14	The time has come: sparing injectables in paediatric MDR-TB. <i>Lancet Respiratory Medicine</i> , <b>2017</b> ,	35.1	2
13	Opportunities for Mobile App-Based Adherence Support for Children With Tuberculosis in South Africa. <i>JMIR MHealth and UHealth</i> , <b>2020</b> , 8, e19154	5.5	2
12	Coronavirus Disease 2019 (COVID-19) Pharmacologic Treatments for Children: Research Priorities and Approach to Pediatric Studies. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, 1067-1073	11.6	2
11	Stability of Second-Line Tuberculosis Medications Mixed With Milk or Yogurt. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 65, 704-705	11.6	1
10	The determination of capreomycin in human plasma by LC-MS/MS using ion-pairing chromatography and solid-phase extraction. <i>Biomedical Chromatography</i> , <b>2018</b> , 32, e4269	1.7	1

9	Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 722204	5.6	1
8	Mitigating the Impacts of COVID-19 on Global Child Health: a Call to Action. <i>Current Tropical Medicine Reports</i> , <b>2021</b> , 8, 1-7	5	1
7	Caregiver-child separation during tuberculosis hospitalisation: a qualitative study in South Africa. <i>South African Journal of Psychology</i> , <b>2021</b> , 51, 409-421	0.7	1
6	Trends in Drug Resistance in Childhood Tuberculosis in Cape Town, South Africa. <i>Pediatric Infectious Disease Journal</i> , <b>2020</b> , 39, 604-608	3.4	0
5	Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial.. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2022</b> , e0214421	5.9	0
4	In reply: Acquired drug-resistance because of pharmacokinetic variability in a young child with tuberculosis. <i>Pediatric Infectious Disease Journal</i> , <b>2014</b> , 33, 1205-6	3.4	
3	Pediatric COVID-19 Therapeutics: Seizing the Right Research and Development Opportunities to Accelerate Access for Children. <i>Pediatric Infectious Disease Journal</i> , <b>2022</b> , 41, e1-e5	3.4	
2	Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 436-445	11.6	
1	Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2022</b> , e0226421	5.9	